Company Introduction
Company introduction
Medytox
Toxin, Filler and Even More
We are at the forefront of Korean biopharmaceutical industry,
thanks to our excellent R&D capabilities based on our top-tier
biotechnologists, and to our state-of-the-art operations and production
facilities. Moreover, we are going to become a trailblazer in the field
of biotechnology due to our passion and courage to embrace global
challenges.
Since Botulinum Toxin Type A Neuronox (Neuronox is also being sold
worldwide under different brand names such as Siax, Botulift, Cunox
and Meditoxin) was launched in 2006, Medytox has shown a dramatic
growth.
Since 2009, we have ranked No. 1 market share in Korea and reached
near 40% of market share. As more diverse indications are added, it
appears that our market share would further increase.
Our company has successfully developed the fourth botulinum toxin
biopharmaceuticals in the world. We are exporting the products to
about 50 countries, including Japan, Thailand, India and Brazil. We are
also expecting to be a leading global biopharmaceutical company after
entering the North America and EU markets in 2016.
CEO
Jung Hyun Ho
Location
641-4 Gak-ri, Ochang-eup,
Cheongwon-gun, Chungbuk 363-
883, Korea
Homepage
www.medytox.com
50
Products
Products Details
Medytox’s core business area is manufacturing botulinum toxin
type A biopharmaceuticals, Neuronox. It is widely used not only
Botulinum Toxin Type A
product
in the cosmetic field, including facial wrinkle reduction, but also
in the therapeutic field, for people with blepharospasm, cerebral
palsy, etc.
Medytox’s hyaluronic acid filler, Neuramis is currently being used
in the field of cosmetics to smoothen deep and fixed wrinkles on
Hyaluronic Acid skin tissue. Also, it is used as therapeutic agent for surgery and for
Dermal Filler treatment of arthritis.
As a partner product, it could maximize a synergy effect along
with Medytox’s core product Neuronox.
R&D Pipeline
Fueled by the success of Nueronox, we plan to perform a basic study for the development of
innovative bio pharmaceuticals to heal degenerative arthritis, senile ocular disease, skin disease
and cancer. We have strengthened base technology in protein engineering, antibody engineering
and cell biology by recruiting talented personnel. As the first achievement, we have completed
basic verification studies on degenerative arthritis and senile ocular disease (MT202 and MT401).
It appears that they would enter into the pre-clinical phase in 2013. We plan to keep making
investments with a long-term vision to be a global biopharmaceutical leader through development
of innovative drugs.
51